Ferric carboxymaltose is an effective parenteral therapy for iron
deficiency. Because of the limited resorption and side effects of
oral iron supplements parenteral iron preparations are preferred in
post bariatric surgery patients to maintain normal iron levels.
Prolonged hypophosphatemia has been recognised as an adverse effect
of parenteral iron therapy but the exact underlying mechanisms
remain to be defined.
After bariatric surgery, secondary hyperparathyroidism caused by inadequate calcium intake and/or vitamin D insufficiency predispose to hypophosphatemia. Thus, post-bariatric patients are likely to be at increased risk to develop significant hypophosphatemia following parenteral iron therapy with ferric carboxymaltose.
The current study is designed to study the frequency, severity and time course as well as the clinical sequelae of hypophosphatemia in a prospective cohort of post-bariatric patients.
|type of project||clinical studies|
|start of project||2016|
|end of project||2018|
|responsible person||Dr. med Stefan Bilz|